Supriya Lifescience
Leading developer of generic APIs and FDFs with global regulatory approvals and a diverse product portfolio.
| INR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 24 % | 35 % | (11 %) | 24 % | 22 % | 20 % | 20 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 46 % | 42 % | 30 % | 32 % | 39 % | 33 % | 33 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 32 % | 29 % | 19 % | 21 % | 27 % | 24 % | 24 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Supriya Lifescience Limited, headquartered in Mumbai, India, is a public listed company specializing in the development and commercialization of generic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Established in 1987, the company operates in the pharmaceutical industry, serving a global clientele that includes healthcare providers and pharmaceutical companies. Supriya Lifescience's API facility in Lote, Maharashtra, has received multiple approvals from international regulatory bodies such as the USFDA, EDQM, EUGMP, and Health Canada, ensuring compliance with stringent quality standards.
The company's business model revolves around the production and sale of over 38 different APIs, which are used to treat various diseases and infections. These products are trusted by a loyal customer base worldwide. Revenue is generated through the sale of these APIs and FDFs to pharmaceutical companies and healthcare providers, who then use them in the production of medications.
Supriya Lifescience is committed to continuous improvement and innovation, as evidenced by its receipt of several national awards for excellence in R&D and entrepreneurship. The company's facility spans 47,000 square meters and includes dedicated areas for warehousing, quality assurance, quality control, research and development, production, and finished products. This infrastructure supports the company's mission to deliver high-quality pharmaceutical products while contributing to social upliftment and creating opportunities for a larger section of society.
Keywords: generic APIs, FDFs, pharmaceutical, global clientele, regulatory approvals, quality standards, continuous improvement, healthcare ecosystem, innovation, social upliftment.